Nycomed

Part of Takeda

CompanySwitzerlandFounded 1874

Nycomed develops one asset, in phase 3 (parathyroid hormone in osteoporosis). Mostly peptide acting on PTH1R; based in Switzerland, founded in 1874.

1
Asset
Furthest stage: Phase 3; 2
Trials: 0
Signals

Pipeline

1

parathyroid hormone
PTH receptor agonist delivered transdermally to stimulate bone formation
Phase 3, Peptide, PTH1R, osteoporosis, primary osteoporosis

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials2
Similar companies6